After obtaining approval for an injected version, Novo Nordisk is now getting ready to launch what could be the first oral version of a GLP-1 drug to treat type 2 diabetes
A growing patient population, evolving clinical guidelines, and integration of technology will support sustained market expansion - but stakeholders must navigate persistent challenges in pricing, access, and adherence to fully unlock future opportunities
Getting Started with GLP-1 Therapy Ready to begin
Ti to v phc hi da Nh vo kh nng ti to t bo v phc hi da, Dagous L-glutathione 500mg h tr lm mi ln da, gip da lun trong trng thi sn chc v khe mnh
Fortified drinks and foods may include plantbased milks, cereals, nutrition shakes, and energy drinks